- Home
- AKTX vs INKT Comparison
AKTX vs INKT Comparison
Compare AKTX & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- INKT
- Stock Information
- Founded
- AKTX N/A
- INKT 2017
- Country
- AKTX United States
- INKT United States
- Employees
- AKTX N/A
- INKT N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- AKTX Health Care
- INKT Health Care
- Exchange
- AKTX Nasdaq
- INKT Nasdaq
- Market Cap
- AKTX 41.8M
- INKT 28.9M
- IPO Year
- AKTX N/A
- INKT 2021
- Fundamental
- Price
- AKTX N/A
- INKT $7.04
- Analyst Decision
- AKTX
- INKT Strong Buy
- Analyst Count
- AKTX 0
- INKT 2
- Target Price
- AKTX N/A
- INKT $37.50
- AVG Volume (30 Days)
- AKTX 28.5K
- INKT 14.8K
- Earning Date
- AKTX 08-18-2025
- INKT 08-12-2025
- Dividend Yield
- AKTX N/A
- INKT N/A
- EPS Growth
- AKTX N/A
- INKT N/A
- EPS
- AKTX N/A
- INKT N/A
- Revenue
- AKTX N/A
- INKT N/A
- Revenue This Year
- AKTX N/A
- INKT N/A
- Revenue Next Year
- AKTX N/A
- INKT N/A
- P/E Ratio
- AKTX N/A
- INKT N/A
- Revenue Growth
- AKTX N/A
- INKT N/A
- 52 Week Low
- AKTX $0.85
- INKT $4.56
- 52 Week High
- AKTX $4.40
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- AKTX 41.94
- INKT 40.47
- Support Level
- AKTX $1.10
- INKT $6.91
- Resistance Level
- AKTX $1.18
- INKT $7.51
- Average True Range (ATR)
- AKTX 0.07
- INKT 0.30
- MACD
- AKTX 0.00
- INKT -0.04
- Stochastic Oscillator
- AKTX 35.50
- INKT 0.00
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.